Responses

PDF

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Important errors in "Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review" by Farrimond et al.
    • George T. Grossberg, Director, Geriatric Psychiatry
    • Other Contributors:
      • Yvonne Wirth, Suzanne Hendrix, Michael Tocco, Stephen M. Graham

    George T. Grossberg, MD, St. Louis University School of Medicine, St Louis, Missouri, USA

    Yvonne Wirth, MD, PhD, Wirth Consulting, Stuttgart, Germany

    Suzanne Hendrix, PhD, Pentara Corporation, Salt Lake City, Utah, USA

    Michael Tocco, PhD, Forest Research Institute, Jersey City, New Jersey, USA

    Stephen M. Graham, PhD, Forest Research Institute, Jersey City, New Jersey, USA

    D...

    Show More
    Conflict of Interest:
    None declared.